- ►diabetesjournals.org S Snitker, RM Watanabe, I Ani, AH Xiang, A … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—The mean changes in S i in the bottom, middle, and top tertiles of S i
response were −0.21 ± 0.57, 0.91 ± 0.26, and 2.58 ± 1.32 min −1 per
μU/ml · 10 −4 , respectively. Frequencies of the Ala/− genotype were ... Cited by 40 - Related articles - BL Direct - All 5 versions
- Free from Publisher M Blüher, G Lübben, R Paschke - Diabetes Care, 2003 - Am Diabetes Assoc RESEARCH DESIGN AND METHODS—A total of 131 patients were treated in an
open-label, randomized, multicenter study with pioglitazone (45 mg od) during a
course of ≥26 weeks. Response to the pioglitazone therapy was defined by ... Cited by 43 - Related articles - BL Direct - All 5 versions
ES Kang, SY Park, HJ Kim, CS Kim, CW Ahn, … - Clinical pharmacology and therapeutics, 2005 - 134.68.189.85 Objective: The aim of this study was to examine the effects of the Pro12Ala
polymorphism of the peroxisome proliferator–activated receptor (PPAR) 2 gene
on the response to rosiglitazone in patients with type 2 diabetes mellitus. ... Cited by 32 - Related articles - View as HTML - All 8 versions
S Snitker, RM Watanabe, I Ani, AH Xiang, A … - Diabetes Care, 2004 - Am Diabetes Assoc OBJECTIVE — We have tested whether the Pro12Ala variant of the peroxisome
proliferator– activated receptor (PPAR)- nuclear receptor involved in
thiazolidinedione (TZD) action ac- counted for the failure of troglitazone ... Cited by 1 - Related articles
- ►endojournals.org JC Florez, KA Jablonski, MW Sun, N Bayley, … - Journal of Clinical Endocrinology & Metabolism, 2007 - Endocrine Soc Context: The common P12A polymorphism in PPARG (a target for thiazolidinedione
medications) has been consistently associated with type 2 diabetes. ...
Objective: We examined whether PPARG P12A affects progression from impaired ... Cited by 41 - Related articles - BL Direct - All 7 versions
- ►shouxi.net JK Wolford, KA Yeatts, SK Dhanjal, MH … - Diabetes, 2005 - Am Diabetes Assoc Thiazolidinediones (TZDs) are peroxisome proliferator–activated receptor-γ
(PPARG) agonists used to treat type 2 diabetes. TZDs can also be used to reduce
rates of type 2 diabetes in at-risk individuals. However, a large fraction ... Cited by 31 - Related articles - BL Direct - All 5 versions
- ►pubget.com [PDF] - Free from Publisher ES Kang, SY Park, HJ Kim, CW Ahn, M Nam, … - Diabetes Care, 2005 - Am Diabetes Assoc RESULTS —Regarding SNP45, there was a smaller reduction in the fasting plasma
glucose (FPG) level and the HbA 1c value in the carriers of the GG genotype than
in the carriers of the other genotypes (P = 0.031 and 0.013, respectively). ... Cited by 53 - Related articles - All 9 versions
- ►endojournals.org L Hansen, CT Ekstrom, R Tabanera y … - Journal of Clinical Endocrinology & Metabolism, 2006 - Endocrine Soc Context: Activation of peroxisome proliferator-activated receptors (PPARs)- by
thiazolidinediones (pioglitazone, rosiglitazone) and dual-acting PPAR / agonists
(pargluva, ragaglitazar) is a widely used pharmacological principle to ... Cited by 18 - Related articles - BL Direct - All 2 versions
G Wang, X Wang, Q Zhang, Z Ma - International Journal of Clinical Practice, 2007 - interscience.wiley.com To investigate the influence of the S447X variant in lipoprotein lipase (LPL)
gene on the response rate to therapy with the thiazolidinedione pioglitazone. A
total of 113 diabetic patients were treated with pioglitazone 30 mg for 10 ... Cited by 11 - Related articles - BL Direct - All 4 versions
- Free from Publisher G Sesti, MA Marini, M Cardellini, A Sciacqua, … - Diabetes Care, 2004 - Am Diabetes Assoc RESULTS—Of the total patients, 53 (11.1%) were heterozygous for the Arg 972
IRS-1 variant, 1 (0.2%) was homozygous, and the remainder (88.7%) were
homozygous for the wild-type allele. The genotype frequency of the Arg 972 ... Cited by 23 - Related articles - BL Direct - All 5 versions
